📰
Lung cancer: the latest breakthroughs
Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.
🤖What changed
Written by AI from the evidence below, every point cited
2026-10-26
Recent phase 3 trial results broaden the use of immunotherapy across neoadjuvant, adjuvant, and refractory settings in non‑small cell lung cancer.
- Neoadjuvant atezolizumab combined with chemotherapy improved outcomes versus placebo plus chemotherapy in resectable stage II–IIIB NSCLC (IMpower030).
Demonstrates that adding PD‑L1 blockade before surgery can increase pathological response and potentially extend survival. NCT03456063 - Adjuvant durvalumab (MEDI4736) after complete resection of NSCLC showed a benefit compared with placebo.
Suggests that postoperative PD‑L1 inhibition may lower recurrence risk and improve disease‑free survival. NCT02273375 - Cobolimab plus dostarlimab and docetaxel improved outcomes versus docetaxel alone in patients who progressed after prior anti‑PD‑(L)1 therapy.
Provides a new therapeutic option for heavily pre‑treated NSCLC patients with limited alternatives. NCT04655976 - Adding atezolizumab to standard radiation therapy for early-stage NSCLC yielded positive trial results.
Combining immunotherapy with radiation may enhance local tumor control and reduce recurrence. NCT04214262 - Tiragolumab (anti‑TIGIT) plus atezolizumab after adjuvant platinum‑based chemotherapy showed benefit over atezolizumab alone in completely resected NSCLC.
Targeting the TIGIT pathway may further boost immune response after standard adjuvant treatment. NCT06267001 - Neoadjuvant osimertinib, with or without chemotherapy, demonstrated efficacy compared with chemotherapy alone in EGFR‑mutant resectable NSCLC.
Integrating a third‑generation EGFR inhibitor early in treatment may increase tumor shrinkage before surgery. NCT04351555
What to watch next
- Long‑term overall survival and disease‑free survival data from the IMpower030 neoadjuvant atezolizumab trial (NCT03456063).
- Updated overall survival and safety data from the adjuvant durvalumab (MEDI4736) trial (NCT02273375).
- Further results on the tiragolumab plus atezolizumab combination in the adjuvant setting (NCT06267001).
- US label updates for lung‑cancer drugs that may reflect new indications or safety information.
💛 Several large phase 3 studies have recently reported results, showing that immunotherapy is being tested in earlier disease stages and after prior treatments. Discuss these new data with your oncologist to understand whether any of these approaches might be relevant to your care.
🤖Written by AI from the public sources cited on this page. It may be incomplete or wrong, it is not medical advice, and it does not know you. Discuss it with your doctor before making any decision. Terms of use
HealthTeky